Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female of 18 to 85 years of age (inclusive);
Have a diagnosis of FAP
Neuropathy Impairment Score requirement of 5-130
Meet Karnofsky performance status requirements
Have adequate complete blood counts and liver function tests
Have adequate cardiac function
Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)
You may not be if
Had a prior liver transplant or is planned to undergo liver transplant during the study period;
Has untreated hypo- or hyperthyroidism;
Has known human immunodeficiency virus (HIV) infection;
Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;
Recently received an investigational agent or device
Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid
Clareo Health | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
